PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)

ANNÉE

2021

AUTEURS

Ducreux Ml, Parzy A, Ben Abdelghani M, Martin-Babau J, Tougeron D, Botsen D, Taieb J, Pannier D, Khemissa F, Viaud J, Villing AL, Bouché O, Peytier A, Alexandre H, Garic F, Tanguy M-L, Bachet J-B

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES